Company intelligence / Profile preview

BiaCure Therapies

Pewaukee, Wisconsin, United Statesbiacure.com ↗

Ownership: Private
Development stage: Preclinical

Overview

BiaCure Therapies is developing the BiaPulse™ device, a non-invasive, high-frequency energy delivery system designed to cure onychomycosis by targeting fungal infections beneath the nail. The company has received a $2.6M NIH SBIR Phase I grant to support further development and validation of its technology through preclinical and early-stage clinical studies. The approach aims to offer a faster, safer alternative for patients who have failed or cannot tolerate oral antifungal medications[3][5][6].

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

BiaPulse

Pre-clinical

Indications: Onychomycosis

Partnerships

National Institutes of Health (NIH) – SBIR grant collaboration[3]

Beyond the preview

Go deeper on BiaCure Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiaCure Therapies.

Explore the full profile